Abstract
Pathologic (path) response (resp) is an excellent surrogate marker for long-term recurrence-free survival after neoadjuvant (neoadj) IPI + NIVO in stage III melanoma. Few resp pts develop recurrence of disease, and their clinical characteristics and mechanisms of tumor immune escape are unknown.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have